JP2005538690A - 腫瘍の治療用の自己ワクチンの調製のための長いペントラキシンｐｔｘ３機能性誘導体 - Google Patents
腫瘍の治療用の自己ワクチンの調製のための長いペントラキシンｐｔｘ３機能性誘導体 Download PDFInfo
- Publication number
- JP2005538690A JP2005538690A JP2003571309A JP2003571309A JP2005538690A JP 2005538690 A JP2005538690 A JP 2005538690A JP 2003571309 A JP2003571309 A JP 2003571309A JP 2003571309 A JP2003571309 A JP 2003571309A JP 2005538690 A JP2005538690 A JP 2005538690A
- Authority
- JP
- Japan
- Prior art keywords
- ptx3
- derivative
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 title claims abstract description 51
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 title claims abstract description 51
- BFHAYPLBUQVNNJ-UHFFFAOYSA-N Pectenotoxin 3 Natural products OC1C(C)CCOC1(O)C1OC2C=CC(C)=CC(C)CC(C)(O3)CCC3C(O3)(O4)CCC3(C=O)CC4C(O3)C(=O)CC3(C)C(O)C(O3)CCC3(O3)CCCC3C(C)C(=O)OC2C1 BFHAYPLBUQVNNJ-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 36
- 229960005486 vaccine Drugs 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 54
- 239000012528 membrane Substances 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 20
- 101100192405 Mus musculus Ptx3 gene Proteins 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 16
- 108700025763 PTX3 Proteins 0.000 claims description 13
- 239000002299 complementary DNA Substances 0.000 claims description 12
- 239000011616 biotin Substances 0.000 claims description 10
- 229960002685 biotin Drugs 0.000 claims description 10
- 235000020958 biotin Nutrition 0.000 claims description 10
- 150000002632 lipids Chemical class 0.000 claims description 10
- 239000002502 liposome Substances 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- 239000002738 chelating agent Substances 0.000 claims description 9
- 101100352284 Homo sapiens PITX3 gene Proteins 0.000 claims description 8
- 101100031710 Homo sapiens PTX3 gene Proteins 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 230000012010 growth Effects 0.000 claims description 7
- 108090001008 Avidin Proteins 0.000 claims description 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 238000007920 subcutaneous administration Methods 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 101100451087 Acetobacter pasteurianus hisC gene Proteins 0.000 description 13
- 101150118121 hisC1 gene Proteins 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 9
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 101100070731 Bradyrhizobium diazoefficiens (strain JCM 10833 / BCRC 13528 / IAM 13628 / NBRC 14792 / USDA 110) hisE2 gene Proteins 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000013600 plasmid vector Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- UVGHPGOONBRLCX-NJSLBKSFSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-NJSLBKSFSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 101150095640 PTX3 gene Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 230000005709 nerve cell growth Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 102000041715 pentraxin family Human genes 0.000 description 1
- 108091075331 pentraxin family Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2002RM000109A ITRM20020109A1 (it) | 2002-02-28 | 2002-02-28 | Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori. |
| PCT/IT2003/000104 WO2003072603A2 (en) | 2002-02-28 | 2003-02-25 | Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005538690A true JP2005538690A (ja) | 2005-12-22 |
| JP2005538690A5 JP2005538690A5 (enExample) | 2006-04-06 |
Family
ID=11456119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003571309A Pending JP2005538690A (ja) | 2002-02-28 | 2003-02-25 | 腫瘍の治療用の自己ワクチンの調製のための長いペントラキシンｐｔｘ３機能性誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090110666A1 (enExample) |
| EP (1) | EP1478661A2 (enExample) |
| JP (1) | JP2005538690A (enExample) |
| KR (1) | KR20040099291A (enExample) |
| AR (1) | AR038854A1 (enExample) |
| AU (1) | AU2003214645A1 (enExample) |
| CA (1) | CA2475526A1 (enExample) |
| IT (1) | ITRM20020109A1 (enExample) |
| MX (1) | MXPA04008217A (enExample) |
| PL (1) | PL372719A1 (enExample) |
| TW (1) | TWI293958B (enExample) |
| WO (1) | WO2003072603A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20040858A1 (it) | 2004-04-29 | 2004-07-29 | Farma Dev S R L | Anticorpi monoclonali ibridomi metodo migliorato per determinare la proteina ptx3 e kit per detta determinazione |
| ITRM20040489A1 (it) * | 2004-10-08 | 2005-01-08 | Sigma Tau Ind Farmaceuti | Pentraxina lunga ptx3 deglicosilata o desialidata. |
| SI1973944T1 (sl) * | 2006-01-24 | 2016-07-29 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | FGF2 vezavni peptidi in njihova uporaba |
| US9226960B2 (en) | 2010-04-16 | 2016-01-05 | Andrew B. Bush | FGF modulation of in vivo antibody production and humoral immunity |
| US8435525B1 (en) * | 2010-04-16 | 2013-05-07 | Andrew B. Bush | FGF modulation of in vivo antibody production and humoral immunity |
| TWI531375B (zh) | 2015-05-29 | 2016-05-01 | 國立成功大學 | 抑制癌細胞活性之短肽治療劑及含此之醫藥組成物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849478A (en) * | 1986-08-14 | 1998-12-15 | Cashman; Daniel P. | Blocked-polymerase polynucleotide immunoassay method and kit |
| US5290551A (en) * | 1990-05-08 | 1994-03-01 | Thomas Jefferson University | Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten |
| IT1298487B1 (it) * | 1997-12-19 | 2000-01-10 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale, |
| IT1317927B1 (it) * | 2000-11-03 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni. |
| IT1317930B1 (it) * | 2000-11-08 | 2003-07-15 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione |
| US20020122820A1 (en) * | 2001-01-16 | 2002-09-05 | Hildebrand William H. | Soluble MHC artificial antigen presenting cells |
| AU2002324328B2 (en) * | 2001-08-03 | 2007-09-06 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of long pentraxin PTX3 for treating female infertility |
| US7041648B2 (en) * | 2001-08-03 | 2006-05-09 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Compositions and methods for treating female fertility |
| ITRM20020191A1 (it) * | 2002-04-08 | 2003-10-08 | Sigma Tau Ind Farmaceuti | Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att |
| US20040137544A1 (en) * | 2002-10-31 | 2004-07-15 | Roberto Latini | PTX3 as an early prognostic indicator of cardiovascular and cerebrovascular pathologies |
| ITRM20030596A1 (it) * | 2003-12-23 | 2005-06-24 | Sigma Tau Ind Farmaceuti | Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3. |
| US20070023879A1 (en) * | 2005-07-29 | 2007-02-01 | Vinayak Pandey | Single unit heat sink, voltage regulator, and package solution for an integrated circuit |
-
2002
- 2002-02-28 IT IT2002RM000109A patent/ITRM20020109A1/it unknown
-
2003
- 2003-02-20 TW TW092103564A patent/TWI293958B/zh active
- 2003-02-25 US US10/506,046 patent/US20090110666A1/en not_active Abandoned
- 2003-02-25 AU AU2003214645A patent/AU2003214645A1/en not_active Abandoned
- 2003-02-25 CA CA002475526A patent/CA2475526A1/en not_active Abandoned
- 2003-02-25 PL PL03372719A patent/PL372719A1/xx unknown
- 2003-02-25 MX MXPA04008217A patent/MXPA04008217A/es unknown
- 2003-02-25 JP JP2003571309A patent/JP2005538690A/ja active Pending
- 2003-02-25 EP EP03710225A patent/EP1478661A2/en not_active Withdrawn
- 2003-02-25 WO PCT/IT2003/000104 patent/WO2003072603A2/en not_active Ceased
- 2003-02-25 KR KR10-2004-7013464A patent/KR20040099291A/ko not_active Ceased
- 2003-02-27 AR ARP030100642A patent/AR038854A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200303755A (en) | 2003-09-16 |
| EP1478661A2 (en) | 2004-11-24 |
| WO2003072603A2 (en) | 2003-09-04 |
| PL372719A1 (en) | 2005-07-25 |
| CA2475526A1 (en) | 2003-09-04 |
| WO2003072603A3 (en) | 2004-03-18 |
| US20090110666A1 (en) | 2009-04-30 |
| AR038854A1 (es) | 2005-01-26 |
| MXPA04008217A (es) | 2004-11-26 |
| WO2003072603A9 (en) | 2004-10-07 |
| AU2003214645A1 (en) | 2003-09-09 |
| AU2003214645A8 (en) | 2003-09-09 |
| KR20040099291A (ko) | 2004-11-26 |
| ITRM20020109A0 (it) | 2002-02-28 |
| ITRM20020109A1 (it) | 2003-08-28 |
| TWI293958B (en) | 2008-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100590131C (zh) | 用于将蛋白定向到胞外体的方法和化合物 | |
| JP4723722B2 (ja) | ワクチン用アジュバントとしてのｍｈｃクラスｉｉリガンドの使用および癌治療におけるｌａｇ−３の使用 | |
| US10688165B2 (en) | Medicament for use in a method of inducing or extending a cellular cytotoxic immune response | |
| EP2231180B1 (en) | Vaccine for alzheimer's disease | |
| JP2024036364A (ja) | Ｉ型インターフェロン遺伝子を刺激するための方法及びカチオン性脂質を含む組成物 | |
| DE60128070T2 (de) | Impfstoff spezifisch gegen nierentumore, gerichtet gegen das antigen g-250 des nierentumors | |
| JP7633930B2 (ja) | 抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ－ｋ由来抗原 | |
| CN118355037A (zh) | Ccl13的用途 | |
| JP4138073B2 (ja) | ヒト癌退縮抗原タンパク質 | |
| JP2005538690A (ja) | 腫瘍の治療用の自己ワクチンの調製のための長いペントラキシンｐｔｘ３機能性誘導体 | |
| KR102297440B1 (ko) | 표적 세포 특이적으로 결합하여 다중 면역기능이 강화된 키메라항원 및 이의용도 | |
| CN111150841B (zh) | 一种主动免疫调控微粒及其制备方法和应用 | |
| CA2440610C (en) | Induction of tumor immunity by variants of folate binding protein | |
| JP2024161435A (ja) | Ｍｈｃおよび腫瘍抗原を同時発現する抗原提示細胞を含む組成物およびこれを用いた癌治療 | |
| US20040022813A1 (en) | Shed antigen vaccine with dendritic cells adjuvant | |
| CN110168086B (zh) | 疟疾疫苗 | |
| JP2007537143A (ja) | アンジオモチンまたはアンジオモチンをコードするポリヌクレオチドを含むワクチン組成物、および、ワクチン組成物の血管新生に関連した病気の治療のための使用 | |
| EP4346883A1 (en) | Methods of treating or preventing autoimmune diseases | |
| CN115850377A (zh) | 基于nras基因q61k突变的肿瘤新抗原多肽及其应用 | |
| JP2006516258A (ja) | ワクチンおよび抗腫瘍ワクチンを調製する方法 | |
| WO2007081301A2 (en) | Methods and compositions related to the identification of a novel il-12 inducing protein isolated from toxoplasma gondii | |
| JPWO2003000894A1 (ja) | ポリヌクレオチドワクチン | |
| JP7513303B2 (ja) | 腫瘍免疫増強剤、その調製方法および適用 | |
| US6514493B1 (en) | cDNA clone for tumor rejection antigen gp110 and tumor peptide vaccine | |
| CN116948005A (zh) | 一种病毒递送的新型细胞因子及在肿瘤治疗中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060220 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080924 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081222 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090507 |